Pomalidomide combinations are a safe and effective option after daratumumab failure.

Annamaria BrioliLaura GengenbachKatia Mancuso Mascha Binder Thomas Ernst Florian H HeidelThomas StauchElena Zamagni Inken Hilgendorf Andreas Hochhaus Monika EngelhardtMarie von Lilienfeld-Toal

Published in: Journal of cancer research and clinical oncology (2023)

These data show that pomalidomide-based combinations can be an effective and safe salvage regimen for daratumumab-refractory patients, including those with EMM.

Keyphrases

multiple myeloma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
electronic health record
patient reported outcomes
machine learning